Lucera Erick — SEC Form 4 filings

SEC reporting owner CIK 1697616. 17 Form 4 filings on record with FilingPulse; latest filed 2026-08-17.

Transaction summary — filings shown

Covers all 17 filings on record, filed 2024-03-05 to 2026-08-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Dyne Therapeutics, Inc. (DYN)Chief Financial Officer64 legs · 11,334 sh · $228,6764
Editas Medicine, Inc. (EDIT)EVP, CHIEF FINANCIAL OFFICER42 legs · 26,446 sh · $132,4345
Beyond Air, Inc. (XAIR)Director51 leg · 39,266 sh · $15,56532
SAB Biotherapeutics, Inc. (SABS)Director22

Form 4 filings — Lucera Erick

FiledFormIssuerReported transactionsSource
2026-08-174Dyne Therapeutics, Inc. (DYN)Sale (S): 1,797 @ $26.28EDGAR
2026-06-264Dyne Therapeutics, Inc. (DYN)Sale (S): 2,362 @ $20.37EDGAR
2026-05-144Dyne Therapeutics, Inc. (DYN)Sale (S): 1,448 @ $18.36EDGAR
2026-04-034Dyne Therapeutics, Inc. (DYN)Sale (S): 5,727 @ $18.64EDGAR
2026-02-174Dyne Therapeutics, Inc. (DYN)Grant/award (A): 65,000 @ $0 · Grant/award (A): 105,000 (derivative) @ $0EDGAR
2025-12-184SAB Biotherapeutics, Inc. (SABS)Grant/award (A): 150,000 (derivative) @ $0EDGAR
2025-11-064Beyond Air, Inc. (XAIR)Disposition to issuer (D): 2,250 (derivative) · Grant/award (A): 2,250 (derivative) · Disposition to issuer (D): 2,000 (derivative) · Grant/award (A): 2,000 (derivative) · Disposition to issuer (D): 1,500 (derivative) · Grant/award (A): 1,500 (derivative) · +10 moreEDGAR
2025-04-014Dyne Therapeutics, Inc. (DYN)Grant/award (A): 66,100 @ $0 · Grant/award (A): 214,500 (derivative) @ $0EDGAR
2025-03-284Beyond Air, Inc. (XAIR)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2025-03-274Editas Medicine, Inc. (EDIT)Grant/award (A): 275,100 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0EDGAR
2025-03-054Editas Medicine, Inc. (EDIT)Sale (S): 4,109 @ $1.71EDGAR
2024-11-264Beyond Air, Inc. (XAIR)Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Grant/award (A): 40,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Grant/award (A): 30,000 (derivative) · +8 moreEDGAR
2024-08-154Beyond Air, Inc. (XAIR)Purchase (P): 39,266 @ $0.40EDGAR
2024-07-174SAB Biotherapeutics, Inc. (SABS)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2024-05-224Editas Medicine, Inc. (EDIT)Sale (S): 22,337 @ $5.61EDGAR
2024-03-214Beyond Air, Inc. (XAIR)Grant/award (A): 45,000 (derivative) @ $0EDGAR
2024-03-054Editas Medicine, Inc. (EDIT)Grant/award (A): 35,300 @ $0 · Grant/award (A): 25,966 @ $0 · Grant/award (A): 106,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1697616 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →